Literature DB >> 7683156

Mapping of heparin-binding structures on bovine herpesvirus 1 and pseudorabies virus gIII glycoproteins.

X Liang1, L A Babiuk, T J Zamb.   

Abstract

The gIII glycoproteins of both bovine herpesvirus 1 (BHV 1) and pseudorabies virus (PrV) mediate the initial and dominant interactions between virus and permissive host cells. By studying virus binding to wild-type and heparin-deficient CHO cells, we demonstrated that the cellular heparin-like moieties play an essential role in BHV 1 and PrV gIII-mediated virus attachment. Subsequent studies were carried out to map the gIII structures that are responsible for heparin binding. First, based on the observation that BHV 1 and PrV are differentially sensitive to heparin inhibition of gIII-mediated attachment to cells, we conducted a gIII domain shuffling experiment. This involved the construction of a set of recombinant BHV 1 expressing BHV 1 and PrV gIII chimeras and then using the sensitivity to heparin inhibition as a means of mapping the potential heparin-binding regions on the gIII molecules. Next, we synthesized panels of partially overlapping BHV 1 and PrV gIII peptides and examined their reactivity to heparin. The results from these experiments demonstrated five heparin-binding sites between amino acid 129 and 310 of BHV 1 gIII and four heparin-binding sites between amino acid 90 and 275 of PrV gIII.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683156     DOI: 10.1006/viro.1993.1254

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Expression of glycoprotein gIII-human decay-accelerating factor chimera on the bovine herpesvirus 1 virion via a glycosyl phosphatidylinositol-based membrane anchor.

Authors:  X Liang; M Tang; T J Zamb; L A Babiuk; J Kowalski; M L Tykocinski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

2.  The porcine humoral immune response against pseudorabies virus specifically targets attachment sites on glycoprotein gC.

Authors:  B T Ober; B Teufel; K H Wiesmüller; G Jung; E Pfaff; A Saalmüller; H J Rziha
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 3.  BHV-1: new molecular approaches to control a common and widespread infection.

Authors:  L Turin; S Russo; G Poli
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

4.  The receptor-binding domain of pseudorabies virus glycoprotein gC is composed of multiple discrete units that are functionally redundant.

Authors:  S J Flynn; P Ryan
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Glycoprotein Bb, the N-terminal subunit of bovine herpesvirus 1 gB, can bind to heparan sulfate on the surfaces of Madin-Darby bovine kidney cells.

Authors:  Y Li; X Liang; S van Drunen Littel-van den Hurk; S Attah-Poku; L A Babiuk
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate.

Authors:  F Z Wang; S M Akula; N P Pramod; L Zeng; B Chandran
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 7.  Protein-glycosaminoglycan interactions: infectiological aspects.

Authors:  D Sawitzky
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

8.  The Importance of Heparan Sulfate in Herpesvirus Infection.

Authors:  Christopher D O'Donnell; Deepak Shukla
Journal:  Virol Sin       Date:  2008-12-01       Impact factor: 4.327

9.  Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.

Authors:  S Laquerre; R Argnani; D B Anderson; S Zucchini; R Manservigi; J C Glorioso
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Identification of cell surface molecules that interact with pseudorabies virus.

Authors:  A Karger; T C Mettenleiter
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.